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Abstract
Background: In Tanzania, many people seek malaria treatment from retail drug sellers. The National Malaria
Control Program identified the accredited drug dispensing outlet (ADDO) program as a private sector mechanism
to supplement the distribution of subsidized artemisinin-based combination therapies (ACTs) from public facilities
and increase access to the first-line antimalarial in rural and underserved areas. The ADDO program strengthens
private sector pharmaceutical services by improving regulatory and supervisory support, dispenser training, and
record keeping practices.
Methods: The government’s pilot program made subsidized ACTs available through ADDOs in 10 districts in the
Morogoro and Ruvuma regions, covering about 2.9 million people. The program established a supply of subsidized
ACTs, created a price system with a cost recovery plan, developed a plan to distribute the subsidized products to
the ADDOs, trained dispensers, and strengthened the adverse drug reactions reporting system. As part of the
evaluation, 448 ADDO dispensers brought their records to central locations for analysis, representing nearly 70% of
ADDOs operating in the two regions. ADDO drug register data were available from July 2007-June 2008 for
Morogoro and from July 2007-September 2008 for Ruvuma. This intervention was implemented from 2007-2008.
Results: During the pilot, over 300,000 people received treatment for malaria at the 448 ADDOs. The percentage
of ADDOs that dispensed at least one course of ACT rose from 26.2% during July-September 2007 to 72.6% during
April-June 2008. The number of malaria patients treated with ACTs gradually increased after the start of the pilot,
while the use of non-ACT antimalarials declined; ACTs went from 3% of all antimalarials sold in July 2007 to 26% in
June 2008. District-specific data showed substantial variation among the districts in ACT uptake through ADDOs,
ranging from ACTs representing 10% of all antimalarial sales in Kilombero to 47% in Morogoro Rural.
Conclusions: The intervention increased access to affordable ACTs for underserved populations. Indications are
that antimalarial monotherapies are being “crowded out” of the market. Importantly, the transition to ACTs has
been accomplished in an environment where the safety and efficacy of the drugs and the quality of services are
being monitored and regulated. This paper presents a description of the pilot program implementation, results of
the program evaluation, and a discussion of the challenges and recommendations that will be used to guide
rollout of subsidized ACT in ADDOs in the rest of Tanzania and possibly in other countries.
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Private sector drug outlets, including drug shops, general
shops, and market vendors, are major sources of medi-
cines in sub-Saharan Africa. A review of studies from
some countries found that around half of caregivers initi-
ally sought medicines for the treatment of common
childhood illnesses from private drug sellers [1].
Historically, in Tanzania, retail drug shops commonly
known as duka la dawa baridi (DLDB) are the most
common source of medicines in the private sector [2].
Because almost no registered pharmacies can be found
outside major urban centers, DLDB provide an essential
service to rural and peri-urban populations who have
limited access to registered pharmacies, and even act as
a safety net when public facilities experience drug stock
outs. The Tanzania Food and Drugs Authority (TFDA)
authorize the estimated 6,800 DLDB to sell non-pre-
scription drugs in the private sector [3]; however, the
majority also illegally stock and dispense an array of
prescription-only drugs [4]. Most DLDB have inade-
quate facilities for properly storing medicines and wide
variation in the quality and prices of medicines available.
Dispensers and owners typically lack qualifications and
training, demonstrate poor adherence to TFDA regula-
tions, and have little or no business knowledge. More-
over, regulation and supervi s i o nb yi n s p e c t o r si so f t e n
inadequate [4,5].
In 2002, the Ministry of Health and Social Welfare
and TFDA worked with Management Sciences for
Health’s (MSH) Strategies for Enhancing Access to
Medicines Program, with funding from the Bill &
Melinda Gates Foundation, to pilot an innovative private
sector drug seller program to transform the DLDB into
government-accredited drug dispensing outlets
(ADDO)–Duka la Dawa Muhimu in Kiswahili. The goal
of the ADDO program is to improve access to afford-
able, quality medicines and pharmaceutical services in
rural and peri-urban areas where there are few or no
registered pharmacies. The accreditation process for
ADDOs takes a holistic approach, with a focus on train-
ing and changing behavior and expectations of those
who use, own, regulate, and work in the drug shops.
The accreditation process involving several key steps
and different stakeholders at various levels has been
described elsewhere [6]. The success of the ADDO pilot
program in the Ruvuma region led to the Ministry of
Health and Social Welfare’sd e c i s i o nt oe x p a n dt h e
ADDO program to all 21 mainland regions of the coun-
try. To date, in addition to the pilot region, ADDOs are
fully functional in seven other regions of Tanzania.
Funding has come from the Government of Tanzania
for rollout in Rukwa and Mtwara regions and from the
U.S. Agency for International Development in Morogoro
region. Other regions have received support from the
Global Fund to Fight AIDS, Tuberculosis and Malaria
and the Danish International Development Agency. In
2009, the government passed a regulation declaring that
all DLDB be phased out by January 2011 (GN. No. 19 of
16
th January 2009) at which time ADDO coverage was
expected to be complete (Figure 1).
Malaria is the biggest public health problem in Tanza-
n i aa n di sr e s p o n s i b l ef o r3 0 %o ft h en a t i o n a ld i s e a s e
burden, 35% of hospitalizations, and 37% of deaths in
children under five years [7]. Tanzania’s 2005 malaria
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Figure 1 Map of Tanzania showing status of ADDO expansion and subsidized ACT distribution (as of December 2008).
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Page 2 of 14treatment policy changed first-line treatment for
uncomplicated malaria from sulfadoxine-pyrimethamine
(SP) to artemisinin-based combination therapy (ACT)–
specifically artemether-lumefantrine (sometimes desig-
nated as ALu). The National Malaria Control Program
(NMCP) subsequently identified the ADDO program as
a potential private sector mechanism to supplement the
distribution of subsidized ACTs in public facilities and
increase access to the first-line antimalarial in rural and
underserved areas [7]. NMCP also views the delivery of
subsidized ACTs through ADDOs as perhaps the best
approach to home-based management of malaria in
Tanzania, because ADDOs can supply affordable and
quality malaria medicines close to where they are
needed and can sensitize communities to the need to
seek early treatment and to adhere to the full course of
treatment [8].
With funding from the Global Fund, in December
2006, Tanzania began providing ACTs through public
and mission health facilities free of charge to all children
u n d e ra g ef i v ea n da tas u b s i d ized price for the rest of
the population [9]. However, a significant access pro-
blem remains for the approximately 35% of Tanzanians
who seek treatment for malaria in the private sector [9].
Availability of ACT products in the private sector had
generally been limited to registered pharmacies in urban
areas where the price of a course of therapy is around
8-10 U.S. dollars (USD)–well beyond the reach of indivi-
duals living in rural and peri-urban communities who
need them the most. This has left millions of Tanza-
nians in rural areas to rely on public sector facilities for
access to the recommended first-line treatment for
malaria, or if they seek treatment from more convenient
retail outlets, to receive suboptimal therapies, primarily
SP, which is more affordable and widely available. Dis-
tribution of subsidized ACTs through ADDOs is seen as
the best way to expand the availability of ACTs through
legally recognized and regulated outlets.
In 2007, with funding from the President’s Malaria
Initiative (PMI) and technical support from MSH’s
Rational Pharmaceutical Management Plus (RPM Plus)
Program, TFDA and NMCP began a pilot program to
make subsidized ACTs available through ADDOs in 10
districts in the Morogoro and Ruvuma regions. At that
time, the National Guidelines for Malaria Diagnosis and
Treatment identified ADDOs as a first-level category
provider of ACT products [7]. The pilot program cov-
ered about 2.9 million people, an estimated 8.4% of the
population of Tanzania. This intervention sought to
capitalize on the ADDO program’s improved systems,
including regulatory and supervisory support, dispenser
training, record keeping practices, and proper drug sto-
rage [5]. The pilot program established a supply of sub-
sidized ACTs, created a price system with a cost
recovery plan, developed a plan to distribute the subsi-
dized products to the ADDOs, trained dispensers on
treatment policy and record keeping related to ACT dis-
pensing, and strengthened adverse drug reaction (ADR)
reporting system. Approximately one year after initia-
tion, MSH collaborated with TFDA to conduct the first
comprehensive review of the pilot program.
The results of the review will provide government sta-
keholders with evidence needed to guide policies related
to increasing access to affordable and effective antima-
larials through the private sector. Specific policy and
implementation issues include ACT packaging and pri-
cing, supply logistics, regulatory oversight and supervi-
sion, training, monitoring drug safety, and behavior
change and communication. In addition, the data on the
subsidization of preferred treatment will provide policy
makers with key information on the effectiveness of that
approach.
Methods
Study area
The pilot program took place in five districts of the
Morogoro region and five districts of Ruvuma region
(Figure 1). The burden of malaria in both regions of the
pilot program is high, with the prevalence of malaria in
children age 6-59 months estimated at 15.7% in Moro-
goro and 23.9% in Ruvuma [10]. Ruvuma was the initial
pilot region for the ADDO program, with the first
ADDOs receiving accreditation in 2003. In Morogoro,
the first shops received accreditation in 2006. In July
2007, ADDOs began supplying subsidized ACTs in
Ulanga and Kilombero districts of Morogoro region and
in the five districts of Ruvuma region. ACT distribution
expanded to three more districts in Morogoro, Kilosa,
Mvomero, and Morogoro Rural, in November 2007,
Morogoro Urban was the only district in the two
regions that was not included in the pilot because the
ADDO accreditation program did not extend to urban
areas pending a policy decision by the Ministry of
Health and Social Welfare to allow ADDOs to operate
near registered pharmacies.
Policy changes
The policy and regulatory environment in Tanzania
allowed the private sector to deliver subsidized ACTs.
The NMCP had already identified the ADDO program
as a potential mechanism to supplement public sector
distribution of subsidized ACTs and increase access in
rural and underserved areas [7]. To allow ADDOs to
dispense ACTs, TFDA added ACT products to the
existing limited list of prescription-only medicines
ADDOs are legally authorized to dispense. RPM Plus
also worked with TFDA to revise the ADDO dispenser’s
manual to reflect the malaria treatment policy change
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Page 3 of 14from SP to ACT. Finally, while artemisinin monothera-
pies have not been as widely used or available in Tanza-
nia as they are in parts of Asia, the TFDA took steps to
stop granting local production and importation permits
for oral dosage forms of artemisinin-based monothera-
pies in August 2008. This action was prompted by con-
cerns over emerging resistance to artemisinin in
S o u t h e a s tA s i aa n dt h ei m p o r t a n c eo fp r e s e r v i n gt h e
efficacy of artemisinin-based products as long as possi-
ble [11].
Packaging and pricing ACTs for ADDOs
Novartis chose to package its ADDO-dispensed product
to look like that used for public sector facilities and to
differentiate it from their commercial sector packaging
of Coartem
®. This decision allowed those visiting either
ADDOs or public clinics to receive the same dosage
instructions and public health messages; however,
NMCP was concerned that using the exact same packa-
ging might result in significant product diversion from
public facilities to ADDOs. To reduce this likelihood, a
tamper-proof sticker was used on subsidized packages
sold in ADDOs, thereby, making it easier for TFDA
inspectors to differentiate the two (Figure 2).
As in the public sector, ADDOs have four different-
colored ACT blister packs that correspond to the differ-
ent doses required according to body weight. To sim-
plify instructions for the ADDOs, however, age
categories were created that approximate the weight
categories for each dose. Table 1 shows information on
age, weight, dose, and price for each of the ACT
packages available in ADDOs. All ADDOs received a
laminated poster providing this information (in Kiswa-
hili), which they are required to display in the shops.
In public health facilities, ACTs are free for children
under five and cost TSH 300 per course of therapy
(USD 0.23) for other patients. This cost excludes the
cost for laboratory tests for malaria diagnosis, which
when indicated, adds TSH 300-500 (USD 0.23-0.38) to
the patient’s cost. Anecdotal evidence suggests that facil-
ities adhere to this price and provide free access to chil-
dren under five. It was determined, however, that for
this pilot, TSH 300 for the course of therapy was too
low for ADDO owners to recover operational costs and
produce a large enough profit margin to provide an
incentive for them to stock the product. We examined
drug shop clients’ ability to pay based on the sales of
other pharmaceuticals sold at ADDOs and reviewed
research examining willingness and ability to pay for
ACTs [12]. ADDO owners were consulted as part of the
price negotiations, and they agreed to a fixed price for
subsidized ACTs (prices for other pharmaceuticals in
t h eA D D O sa r en o tf i x e d ) .A sar e s u l to ft h ea n a l y s i s
and negotiations, the final prices of subsidized ALu dis-
tributed through ADDOs were TSH 1,500 (USD 1.12)
for an adult course of therapy and TSH 500 (USD 0.38)
for a child’s course of therapy.
ACT supply logistics
To procure the supply of ACTs for the pilot program,
PMI negotiated with Novartis, who agreed to supply the
product to be distributed through ADDOs at the same
price as the public sector receives. Procurement for
ADDOs followed the same procedure as procurement in
the public sector, where the consignee fills out and sub-
mits ACT order submission forms to the World Health
Organization. For the pilot program, ACTs were pro-
cured in two consignments, which provided an opportu-
nity to track the first consignment’s sales before
procuring the second consignment. In addition, because
ACTs have a relatively short two-year shelf life, this
ensured that the product in the second consignment
w o u l dh a v ec l o s et ot h ef u l lu s e f u ll i f ea v a i l a b l e .T h e
program negotiated with the TFDA to obtain a waiver
of the 2% importation fee that TFDA charges for all
pharmaceutical imports.
To determine quantities of ACTs needed for ADDOs
for the pilot program, we used the morbidity method of
quantification because no historical data was available
on ACT sales in ADDOs. Therefore, we reviewed dis-
pensing registers from a sample of 78 ADDOs to deter-
mine the number and age of customers who sought
antimalarial treatment during the preceding 12-month
period in Ruvuma and Morogoro regions. Interviews
with owners and dispensers of selected ADDOs pro-
vided additional information. We also reviewed the
Southern Highland Pharmacy’s database in Songea
town, which has a comprehensive record of ADDOs in
Ruvuma region that have purchased from them since
2003. Estimates took into account the transmission
Figure 2 ADDO sticker on ACT blister pack.
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Page 4 of 14patterns of malaria in the two regions and the age-speci-
fic dosage categories for ACTs, which were based on the
NMCP criteria for estimating ACT needs for public
health facilities. RPM Plus estimated that 661,393
courses of treatment would be needed to supply the
approximately 650 ADDOs in the target districts for the
first year.
The plan to distribute ACTs to ADDOs was devel-
oped based on the existing private sector supply chain
in Tanzania, where private pharmaceutical wholesalers
are the main source of pharmaceuticals. Pyramid
Pharma Ltd, based in Dar es Salaam, was chosen as the
ACT distributor for ADDOs based on the following cri-
teria: adequate and secure storage facility, readiness to
track ACT inventory, reliable transportation to regional
sub-distributors, high-quality record keeping, local avail-
ability of a wholesale unit in Ruvuma region, and pre-
vious working experience with major public and private
sector clients. Pyramid Pharma was given responsibility
to receive ACT consignments upon arrival in the coun-
try and to clear, store, and distribute the drugs to the
two regional distributors.
Pyramid Pharma identified Southern Highland Phar-
macy as its subsidiary distributor for Ruvuma region and
Marhaba Pharmaceuticals Ltd for Morogoro region.
These regional distributors were already the main suppli-
ers of ADDOs; 89% of all ADDOs in Ruvuma regularly
procured their pharmaceutical supplies from Southern
Highland pharmacy [13]. To ensure that the regional dis-
tributors correctly supply ACT to the intended ADDOs,
buyers must present their ADDO accreditation certificate
and sign the distributor’s ACT register. The key feature
of the supply system design was a combination of “push”
and “pull.” The national distributor agency (Pyramid
Pharma) “pushes” predetermined quantities of ACTs to
the regional distributors, Southern Highland Pharmacy
and Marhaba Pharmaceuticals Ltd. ADDOs are expected
to “pull” ACT quantities from the regional distributors
based on their needs. This design maximizes private sec-
tor supply chain efficiency by avoiding excess ACT stock
or stock outs because ADDOs can procure drugs based
on their needs during their normal purchasing schedule.
Figure 3 shows a breakdown of the chain of supply for
ACTs in ADDOs.
Regulatory oversight and supervision
Generally, the regulation of ACT distribution through
ADDOs capitalizes on the existing ADDO regulatory
systems. Regulatory oversight and support by district-
and ward-level inspectors help ensure that ADDO dis-
pensers are held accountable for selling ACTs at the
fixed price and for maintaining other ADDO standards.
Supervision, focusing on education and mentoring of
ADDO owners and dispensers, helps strengthen and
maintain the quality of care and is vital to program sus-
tainability. RPM Plus and TFDA trained and mentored
council health management team supervisors at the dis-
trict level to conduct quarterly supervisory visits with
ADDO dispensers with the goal that the council team
would eventually assume all supervisory responsibilities
for ADDO dispensers, including their adherence to the
ACT policy. Specifically, supervisors are supposed to
ensure that ADDOs have ACT management tools on
hand (monthly report forms, referral forms, etc.), pro-
vide technical support related to ACT dispensing, and
evaluate dispensers’ knowledge and skills. The main
challenge with supervision is that the council health
management teams also monitor public health facilities,
but do not receive additional resources to cover trans-
port costs and time needed to monitor ADDOs as well.
The use of ADDO drug registers to record all sales
information helps monitor and quantify ACT sales. In
addition, quarterly report forms were created for ADDO
dispensers to collate information on the number and
age of malaria patients treated and product losses due
to drug expiry. ADDOs are required to submit these
forms quarterly to the regional distributor.
Training ADDO dispensers on ACT policy
Comprehensive training of both dispensers and owners
is already a key requirement for the ADDO accredita-
tion process. In addition to the six-week ADDO dispen-
ser training program that had already taken place in
Morogoro and Ruvuma regions prior to the ACT pilot
program, RPM Plus and TFDA conducted an additional
two-day training course for ADDO dispensers on the
new malaria treatment policy. This training included the
correct usage of ACTs, inventory management, and
reporting on drug consumption, patient-related data,
Table 1 Information on ACTs available in ADDOs
Color of package Age Weight (kg) Dose Retail Price in Tanzanian shillings (TSH)/USD*
Yellow 3 months-3 years 5-15 1 × 6 500/0.38
Blue 3-8 years 15-25 2 × 6 500/0.38
Red 8-12 years 25-35 3 × 6 1,500/1.15
Green 12 years and up 35+ 4 × 6 1,500/1.15
*Based on 2006 foreign exchange rate 1 USD = 1,300 TSH
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Page 5 of 14and ADRs. A total of 1,363 ADDO dispensers from 10
districts attended the training.
Monitoring drug safety
As the availability of ACTs increases in the private sec-
tor through ADDOs, it is impor t a n tt oe n s u r et h a ts y s -
tems are in place to monitor and promote safe and
appropriate use. TFDA already has an established pas-
sive (voluntary) ADR reporting system for medicines
dispensed in public health facilities. To facilitate report-
ing by ADDOs, TFDA approved a simplified ADR
reporting form for ACTs, inclusion of ADR reporting in
ADDO dispenser training, and integration of ADDOs’
ADR data into the district ADR reporting process. RPM
Plus worked with the TFDA and council health manage-
ment teams to link ADDOs with this reporting system.
The ADDO dispenser training on ACT policy change
addressed ADR issues to increase dispensers’ awareness
of the importance of drug safety monitoring and to
instruct them on proper reporting using ADR forms.
Dispensers were also instructed and encouraged on how
to discuss drug safety issues with their clients. At the
time of this evaluation, 20 ADDOs had reported on cus-
tomers’“ minor complaints” (skin rash and upset sto-
mach) to the district authorities. Although these were
nonspecific and might or might not have been related to
Figure 3 Supply and distribution of subsidized ACT products through ADDOs.
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Page 6 of 14taking ACTs, these early results indicated an increased
awareness of the ADR issue.
Behavior change and communication
Behavior change and communication (BCC) activities
were deemed a critical part of this intervention. During
the assessment and planning stages of the pilot, RPM
Plus consulted with NMCP to map out BCC activities
related to malaria and to link this pilot program to
ongoing BCC work to leverage resources and ensure
that a consistent message was being delivered on ACT
policy.
The Communication and Malaria Initiative in Tanza-
nia (COMMIT), which is led by the Johns Hopkins Uni-
versity’s Center for Communication Programs, expanded
their existing BCC activities related to the ACT policy
in Morogoro and Ruvuma regions to include the avail-
ability of ACTs in ADDOs. COMMIT incorporated the
availability of ACTs in ADDOs in road shows in the
two regions and planned further strategies, including
radio broadcasting and the dissemination of printed
materials such as stickers, flyers, and t-shirts. However,
ad e l a yi nt h eC O M M I TB C Cactivities related to
ADDOs meant that the activities did not coincide with
start of ACT distribution, as planned, but instead started
nine months later.
Additionally, the Ifakara Health and Research Devel-
opment Center’s ACCESS program, which works on
malaria projects in two Morogoro districts (Kilombero
and Ulanga), has been using a BCC and social marketing
approach that promotes ACTs as the treatment of
choice for malaria symptoms, refers patients to health
centers to obtain treatment, and emphasizes completing
the full dosage for effective treatment [14].
Program evaluation
Approximately one year after the introduction of subsi-
dized ALu in ADDOs, we planned this evaluation of the
pilot program. One year allowed enough time to
account for fluctuation in ACT consumption due to
malaria seasonal patterns and to identify program bar-
riers and identify recommendations to guide future
delivery of subsidized ACTs in Tanzania’s private sector.
This program evaluation focused on processes in design-
ing private sector subsidized ACT delivery, assessing the
quantities of antimalarials that ADDOs dispensed, and
the efficacy of regulatory and reporting systems related
to ACTs. In addition, the evaluation sought to docu-
ment challenges and lesson learned in launching an
ACT delivery initiative through the ADDO program.
Uptake and availability of ACT in ADDOs
One of the major advantages of the ADDO program is
the improvement in record keeping, which is an
accreditation requirement. Owners are required to keep
records of all purchases and dispensing transactions for
the list of products authorized for sale. To overcome
logistical challenges and reduce the costs associated
with collecting data from each individual ADDO, we
asked ADDO dispensers to bring their drug registers,
ACT purchase reports, and stock cards to central loca-
tions close to their communities. Most locations (pri-
marily primary schools or ward offices) were in peri-
urban areas with a few in villages. ADDO dispensers
spent half a day in the meeting and were able to travel
back to their shop. Prior to the meeting, the district
team sent information such as which records to bring
by calling or text messaging owners. The dispensers did
not receive an allowance for participating, but were pro-
vided refreshments.
Four hundred forty-eight ADDOs from 10 districts
participated in this data collection exercise, 298 in Mor-
ogoro region and 150 in Ruvuma region, representing
nearly 70% of ADDOs in operation in the two regions.
ADDO drug register data were available from July 2007-
June 2008 for Morogoro region and from July 2007-Sep-
tember 2008 for Ruvuma region. The drug register
review was used to extract data on the number and age
of customers who were sold treatment for uncompli-
cated malaria for each month of the period, including
the type of antimalarial dispensed. The evaluation team
also reviewed ACT purchase reports that had been sub-
mitted to the regional distributors. Triangulation of var-
ious records allowed us to verify and crosscheck
discrepancies and accuracy of quantities purchased and
dispensed during any period. Additionally, a question-
naire was administered to the ADDO dispensers to
determine what type of ACTs shops were stocking and
the reasons why. We also asked dispensers about the
availability of ACT tools in their shops, including quar-
terly report forms, standard operating procedures for
ACT purchasing, price indicator sheets, and dosage indi-
cator sheets.
Study limitations
T h ed a t af r o mt h eA D D Od r u gr e g i s t e r ss u f f e r sf r o m
limitations that are common with routine records in
developing countries; however, this intervention
involved working with district teams and ADDO owners
to strengthen supportive supervision and the quality of
data recording related to ACTs in the ADDOs. Regular
teams visited ADDOs and worked with owners to
ensure completeness, accuracy, and timely reporting of
ACTs dispensed.
The participation rate among eligible ADDOs was
around 70%, which was an accomplishment given the
logistical challenges (e.g., owners had to close the shop
to attend). Follow-up with those who did not participate
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about the evaluation workshop from the district health
office, which was confirmed through government
sources; however, other reasons may have contributed
and may have biased the results. No particular geo-
graphic areas lacked participants; no-shows were fairly
evenly distributed. In addition, problems still exist with
ACT sales not being recorded in the drug register; how-
ever, observations from previous supervision visits sug-
gests that this issue is not limited to the ACT program,
but rather is related to overall underreporting of medi-
cine sales to avoid taxes. This under-reporting, however,
may bias overall results.
The distribution of subsidized ACTs though ADDOs
was piloted in all existing ADDOs in the two regions of
Morogoro and Ruvuma to provide information on feasi-
bility and implementation before large-scale nationwide
rollout. One of the key requirements was that the imple-
mentation needed to be designed as a routine activity to
reflect the reality on the ground and to assess its feasi-
bility rather than a strictly controlled design using a
naive region. From routine supervision and monitoring
visits, we had documented that no ACTs were available
in ADDOs prior to the intervention. Because the price
for unsubsidized Coartem had been USD 8-10, none of
the ADDOs could afford to stock it because customers
could not afford to pay.
Results
Uptake and availability of ACT in ADDOs
As mentioned, results are based on data from 448
ADDOs–or about 70% of the total number of ADDOs
in the 10 target districts. Over the pilot program imple-
mentation period (July 2007-September 2008), the 448
ADDOs dispensed antimalarial treatment to over
300,000 customers. Around 30% of malaria treatments
were for children under five. Table 2 presents district-
specific data on ADDO patients.
The percentage of ADDOs that dispensed at least one
course of ACT rose from 26.2% during July-September
2007 to 72.6% during April-June 2008. For the five dis-
tricts in Ruvuma that reported data for July-September
2008, this increased to 81.5%. At the time of the evalua-
tion, dispensers reported that 68% of ADDOs in Moro-
goro and 78% of ADDOs in Ruvuma were stocking at
least one of the four types of ACTs (indicated by yellow,
blue, and red, green packaging). The main reasons they
cited for ADDOs not stocking ACTs included the far
distance to the regional distributor (92%), the high sales
price of ACTs (55%), and the ADDOs’ limited capital
resources (52%). Slow uptake in ADDOs (as reported by
dispensers) was also associated with patient perceptions
that the ACT dosing schedule was difficult (30%) and
the availability of free ACTs at public health facilities
(10%). Only 4% of dispensers cited unavailability of
ACTs at the regional distributor as a reason for not
stocking. Dispensers also demonstrated a high level of
compliance with ACT documentation requirements;
over 80% of ADDO dispensers reported using drug reg-
isters, ACT quarterly report forms, ACT price indicator
sheets, ACT dose indicator sheets, and referral forms.
Evaluation teams verified all the records presented by
ADDO dispensers.
The ADDO data indicated that the number of custo-
mers seeking malaria treatment with ACTs gradually
increased after the start of the pilot program, while the
use of non-ACT antimalarials declined (Figure 4). In the
448 ADDOs reporting, ACTs went from 3% of all anti-
malarials sold in July 2007 to 26% in June 2008. In the
five districts of Ruvuma where data was available up to
September 2008, ACTs comprised 41% of all antimalar-
ial sales in September 2008. Concurrently, sales of the
most common antimalarial, SP, comprised 57% of all
antimalarials distributed in July 2007, decreasing to 49%
in June 2008, and further to 35% in September 2008 (for
the five Ruvuma districts). Small decreases in amodia-
quine and quinine sales were also evident over the inter-
vention period.
District-specific data showed substantial variation
among the districts in ACT uptake through ADDOs,
ranging from ACTs representing 10% of all antimalarial
sales in Kilombero to 47% in Morogoro Rural (Figure 5).
Discussion
This paper attempts to provide policy makers and pro-
gram managers with concrete results from a year-long
pilot program to guide their policy, regulatory, and
implementation decisions for scaling up private sector
delivery of ACTs through ADDOs. Although ADDOs
have been operating in Tanzania on a limited scale since
2003, the use of subsidies in the private sector to pro-
mote the sales of a particular treatment–in this case,
A C T s ,i sn e w ;t h e r e f o r e ,t h i sd a t ai sa ni m p o r t a n tc o n -
tribution to the government’s decisions in relation to
developing a strategy to increase access to ACTs.
As the results of this evaluation show, with extensive
collaboration by numerous stakeholders a sustainable
and reliable system to increase access to ACTs through
the private sector has been established in two regions of
Tanzania, using legally recognized accredited drug
shops, the existing private sector pharmaceutical distri-
bution system, trained drug dispensers, and local super-
visory and regulatory oversight. Additional steps in
program implementation involved procuring subsidized
ACT products, determining packaging and pricing,
training dispensers in the new ACT policy, and estab-
lishing an ADR monitoring system. Preliminary results
showed that the intervention increased access to
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Page 8 of 14Table 2 Number of customers dispensed with antimalarial medicines at ADDOs by district: July 2007-September 2008
Region District # ADDOs
participating
in ACT
delivery
#ADDOs
participating
in ACT
evaluation
# Clients
seen at
ADDOs (all
conditions)
#Recorded clients
dispensed with
antimalarial (% of
total clients)
# Recorded clients dispensed
antimalarial who are children <5 (%
of total clients dispensed with
antimalarial)
Clients
dispensed
with ALu
Clients
dispensed
with SP
Clients
dispensed
with
amodiaquine
Clients
dispensed
with
quinine
Mvomero 71 54 54,979 17,597 (32.0) 5,433 (30.9) 27% 41% 18% 14%
Morogoro
Rural
41 33 43,375 12,703 (29.3) 4,593 (36.2) 47% 29% 13% 11%
Morogoro Ulanga 50 30 83,933 36,100 (43.0) 12,460 (34.5) 19% 54% 18% 9%
Kilombero 126 67 231,021 63,902 (27.7) 28,588 (44.7) 10% 59% 11% 20%
Kilosa 167 134 142,513 43,337 (30.4) 12, 411(28.6) 21% 60% 9% 10%
TOTAL 455 (298)66% 555,821 173,639 (31.2) 63,485(36.6) 19% 55% 12% 14%
Tunduru 25 9 40,980 8,480 (20.7) 3,387 (39.9) 11% 46% 16% 27%
Mbinga 56 43 152,918 51,996 (34.0) 12,637 (24.3) 24% 47% 18% 11%
Ruvuma Songea
Rural
40 34 63,480 21,231 (33.4) 8,925 (42.0) 23% 38% 21% 18%
Namtumbo 26 13 25,068 8,802 (35.1) 3,135 (35.6) 33% 35% 15% 17%
Songea
Urban
58 48 184,945 46,718 (25.3) 11,349 (24.3) 18% 58% 11% 13%
TOTAL 205 (150) 78% 467,391 137,227(29.4) 39,433 (28.7) 22% 48% 16% 14%
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Page 10 of 14affordable ACTs for rural and underserved populations.
In addition, early signs showed that antimalarial mono-
therapies not recommended by NMCP are being
“crowded out” of the market. Importantly, this transition
has been accomplished in an environment where the
safety of the drugs and the quality of services are being
monitored and regulated. While the results of the pilot
program evaluation are encouraging, we have identified
a number of challenges and opportunities for
improvement.
Distribution chain
One year after initiation of the pilot, 70% of ADDOs
that had reported data (which had represented about
7 0 %o ft h et o t a ln u m b e ro fA D D O si nt h et w or e g i o n s )
for this pilot program were stocking ACT products.
This figure exceeded 75% in 6 of the 10 districts. In the
other four districts (Kilombero, Namtumbo, Tunduru,
and Ulanga), the primary reason dispensers said that
ADDOs did not stock ACTs was the long travel distance
to the regional distributor for re-supply. This suggests
that the current distribution system for ACT products,
based on having one regional distributor in each region,
is inadequate to meet the needs of ADDOs with limited
capital or remote locations. For example, in Tunduru
district, only 35% of ADDOs stocked ACTs at the time
of data collection, and 80% of those dispensers cited dis-
tance to the distributor as the reason. In addition, a
number of ADDOs reported having inadequate capital
to procure enough ACTs to last until their next pur-
chase, which is affected by long distances and poor road
conditions.
The best solution for distribution chain problems is to
ensure that more certified wholesalers at the district
level are available to serve ADDOs. Establishing certified
wholesalers is a relatively slow and difficult process; for
example, TFDA requires ADDO restricted wholesalers
are to be supervised by a pharmacist, who is seldom
available in rural areas. An interim option is to revisit
the current requirement and consider allowing lower
pharmaceutical cadres to supervise select ADDOs to
serve as an ACT distributor to more remote ADDOs.
Both strategies would help ensure that ADDO owners
have a shorter distance to travel to obtain ACTs, lower
travel costs, and greater ability to refill their stock. How-
ever, this option has regulatory implications that TFDA
needs to consider carefully.
Sales factors
While the pilot program demonstrated a generally suc-
cessful mechanism to increase the availability of ACTs
in the private sector, the sales of ACT products com-
prised only 26% of overall antimalarial sales in the 10
districts. The two main reasons cited by ADDO
dispensers for the poorer than expected sales included
the high prices of ACTs and the patient’s perceptions of
the drug. In addition, although our results show an
increase in ACT sales at ADDOs, we cannot determine
if this increase indicates an overall increase in ACT use
in the community or merely a shift in access from one
ACT source to ADDOs.
Two studies have examined Tanzanian caregivers’ will-
ingness and ability to pay for ACTs for a sick child: one
found a median level of willingness to pay of TSH 600
(USD 0.46) and the other found a median willingness to
pay of TSH 650 (USD 0.5) [12,15]. This suggests that
the fixed price of TSH 500 (USD 0.38) for the child’s
course of ACT in ADDOs is appropriate. We did not
identify any studies examining willingness to pay for an
adult course of ACT; however, the study by Wiseman et
al. found that 95% of caregivers were unwilling to pay
TSH 1,500 (USD 1.15) (cost of the adult course of ACT
in ADDOs) for a child’s course of ACT [12]. Presum-
ably, a high percentage of people might also be unwill-
ing or unable to pay TSH 1,500 for an adult treatment.
As marketplace prices of SP for adults at the ADDO
level range from TSH 300-1000 (USD 0.23-0.77),
depending on the brand and packaging (loose pills ver-
sus blister pack), one adult course of ACT could cost
the same as up to five treatments with SP.
The subsidized ACTs currently available in Tanzania
have a more complicated dosing schedule than other
common antimalarials, requiring two doses per day for
three days versus a single dose for SP. Depending on
the patient’s age, one treatment comprises between 6-
24 pills. It is not known to what extent the relative
inconvenience of the dosing schedule or other factors
related to the appearance of the drugs or the packaging
deters individuals from purchasing ACTs in ADDOs.
Patient compliance to the proper ACT regimen pur-
chased from ADDOs is also unknown. Further research
examining the social, economic, and cultural factors
affecting malaria treatment decision making would con-
tribute to the design of effective BCC messages and
marketing strategies for the new ACT policy.
During the pilot program monitoring, supervisors
noted that the profit margin for ADDO business owners
for the adult course of therapy of subsidized ACT was
significantly less (28-44%) than that for SP (61-164%)
(See table 3). Thus, some owners may have been reluc-
tant to recommend ACTs to treat malaria and risk los-
ing profits. In March 2009, after reviewing the prices of
ACTs, in consultation with NMCP and TFDA, we
decided to decrease the wholesale and retail prices of all
ACT age categories from TSH 350-1,250 to TSH 200-
700 (wholesale) and from TSH 500-1,500 to TSH 300-
1,200 (retail). The new retail price is about USD 0.23-
0.92. This put the profit margin for ACTs in line with
Rutta et al. Health Research Policy and Systems 2011, 9:22
http://www.health-policy-systems.com/content/9/1/22
Page 11 of 14that of SP (an average of 71%) and may encourage more
dispensers to recommend ACTs to their clients.
Before the start of the subsidy program, other studies
had documented no or very low availability of ACTs in
the private sector, including ADDOs [16]. This interven-
tion provided the first subsidized ACTs to the private
sector market at a price deemed affordable for the
majority of the population living in rural areas. ADDO
dispensers either provide ACTs after they receive pre-
scriptions from health facilities (assuming proper diag-
nosis was done there) or they make a decision to
dispense ACTs for cases of uncomplicated malaria
based on their training and experience. Currently,
ADDO dispensers are not allowed to use a test to diag-
nose malaria.
The overall uptake of ACTs in ADDOs was clearly
undermined by the sales of alternative antimalarials, par-
ticularly SP. Once Tanzania establishes an adequate
ACT supply for the country, it is expected that TFDA
and NMCP will remove SP and other suboptimal anti-
malarials from ADDOs. This should limit the availability
of other antimalarials in the market and increase the
use of ACTs. Discussions continue about whether SP
and other less effective antimalarials should be removed
only after nationwide coverage of subsidized ACTs in
ADDOs has been achieved, or whether the removal pol-
icy can be phased in as regions begin the program.
BCC strategy
The lack of a comprehensive BCC strategy specifically
targeting ACT availability in ADDOs is a significant bar-
rier to encouraging communities to purchase ACTs in
ADDOs to treat uncomplicated malaria. A small pilot
program to distribute subsidized ACTs through DLDB,
carried out by the Clinton Health Access Initiative
(CHAI) in two districts of Tanzania, observed more
rapid uptake of ACTs through DLDB than we observed
in this study. One reason cited in the CHAI study was a
more extensive and focused social marketing campaign
that involved advertising the availability of ACTs in
drug shops through numerous media outlets [17]. The
COMMIT project initiated BCC activities to improve
the use of ACTs in the community and to promote the
availability of subsidized ACTs through ADDOs (Perso-
nal communication, Waziri Nyoni, March 2009). COM-
MIT plans to conduct radio spots and distribute fliers
and posters in the regions that have ADDOs. These
efforts should help disseminate information to commu-
nities about the availability of ACTs in public health
facilities and ADDOs and to encourage the use of ACTs
for uncomplicated malaria.
Dispenser training
The importance of drug seller training is well recog-
nized and has been a vital component of most interven-
tions aimed at improving the quality of services
provided by drug shops and other medicine sellers [4];
however, the comprehensive nature of the six-week
ADDO training program is unique from other medicine
seller interventions, which are generally more narrowly
focused. For example, many of the dispensers in the
CHAI program to distribute ACTs through DLDB had
no formal medical training and only attended two-day
training on malaria and ACTs [17]. In contrast, prior to
the two-day ACT training for this pilot program, ADDO
dispensers already had a minimum of one year of health
training as a nurse assistant and had undergone a six-
week course in general dispensing, pharmaceutical man-
agement, and integrated management of childhood ill-
ness. Their ADDO training covered how to properly
identify and treat malaria, recognize danger signs of
complicated malaria, refer patients to health facilities,
and properly keep records and comply with regulations
governing proper dispensingp r a c t i c e s .W h i l eo u re v a -
luation did not specifically assess ACT dispensing ser-
vices in ADDOs, evidence indicates that the quality of
dispensing services in ADDOs is high, making it more
likely that ADDO dispensers dispense ACTs responsibly
[18]. In regions where the ADDO program has yet to be
initiated, the basic dispenser training course will include
the new ACT guidelines, inventory control practices,
and reporting, which will eliminate the need for a spe-
cial ACT-specific training course.
Regulatory and supervisory support
T h er e g u l a t o r ya n ds u p e r v i s o r ys y s t e m si n h e r e n ti nt h e
ADDO program and then adapted to monitor ACT dis-
pensing make this intervention stand apart from other
interventions to provide subsidized ACTs in private
drug shops. While implementing these systems seems
slow and requires significant financial and human
resources, they help ensure that the population receives
Table 3 Comparison of Antimalarials Price and Percent Mark Up at ADDO
Product Wholesale Price Tsh [$] Retail Price at ADDO Tsh [$] Profit Amount Tsh [$] % Profit Margin
SP 180-500 [0.14-0.38] 500-800 [0.38-0.62] 300-320 [0.23-0.25] 61-164%
Amodiaquine 200-500 [0.15-0.38] 500-800 [0.38-0.62] 300 [0.23] 61-153%
ACT 350-1250 [0.27-0.96] 500-1500 [0.38-1.15] 150-350 [0.12-0.27] 28-44%
Quinine 85 [0.065] 100 [0.076] 15 [0.012] 19%
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goals are met.
NMCP had initially raised ACT leakage as a concern
before the program began; however, during the pilot
program, no leakage of ACTs destined for the public
sector to the ADDOs was identified. To prevent leakage
f r o mt h ep u b l i cs e c t o rt oA D D O so rf r o mA D D O st o
DLDB, a number of safeguards were put in place: (1)
ACTs meant for ADDOs included a special ADDO
sticker (figure 2); (2) ADDO owners had to present their
accreditation certificate to the regional wholesaler to
purchase ACTs; (3) teams monitored sales and reviewed
stock records monthly at the national and regional sup-
pliers; and (4) district- and ward-level inspectors
checked shops for public-sector ACTs (and found none).
Another concern was the potential risk associated with
indiscriminant use of the drugs, which can accelerate
the development of drug resistance and increase the risk
of ADRs [4]. This pilot program addressed these con-
cerns by training dispensers, implementing supervisory
and regulatory systems, and linking ADDOs with an
ADR reporting system.
At the time of writing this paper Tanzania was among
the countries selected to implement the Affordable
Medicines Facility-malaria (AMFm). The AMFm, a price
subsidy mechanism to expand access to affordable
ACTs, is managed by the Global Fund to Fight AIDS,
Tuberculosis and Malaria and has been described else-
where [19,20]. The planned AMFm strategy in Tanzania
has implications for the ADDO program. Currently, in
the private sector only Part 1 pharmacies and ADDOs
can legally stock and dispense ACTs, which makes it
difficult to increase access to ACTs in regions without
ADDOs. TFDA acknowledges the challenges in scaling
up the ADDO program nationwide in a reasonable time
frame. However, TFDA is concerned with an approach
that essentially favors quick results by granting unaccre-
dited shops additional dispensing responsibilities with-
out full accreditation. Disregarding the ADDO
program’s comprehensive system improvements creates
the danger of obstructing the nationwide ADDO imple-
mentation goal. TFDA does not want to send a mixed
message by allowing both DLDB and ADDOs to deliver
subsidized ACTs, especially if the DLDB have not
started the accreditation process. Such an allowance
may create a disincentive for unaccredited shop owners
to participate in the ADDO program, which damages
the program’s chances for sustainability.
This evaluation found that the availability of manage-
ment tools related to ACT dispensing in ADDOs was
high. But while the majority of ADDOs had drug regis-
ters, ACT quarterly report forms, ACT price and dose
indicator sheets, and referral forms, the evaluation sug-
gested the need to improve dispensers’ use of these
tools. For instance, comparing the sales of ACTs
recorded in drug registers with the purchasing slips
from regional distributors indicated that dispensers were
only recording approximately 60% of ACT sales. In
addition, up to 70% of all malaria medicines sold in
ADDOs are in response to written prescriptions from
health facilities presented by patients, but in many
instances, the sales of ACT from these prescriptions
were not recorded in the drug registers. Using SP as an
example, appropriate record keeping could indicate the
percentage of SP sales that resulted from appropriate
prescriptions to pregnant women and what percentage
of sales was inappropriate. Strengthening supervision to
ADDOs and emphasizing the importance of record
keeping will continue to be important to ADDO pro-
gram sustainability.
Conclusions
As Tanzania expands access to effective antimalarial
medicines, particularly in rural areas, ADDOs provide
the mechanism to increase access in the private sector
while ensuring quality of services and products to safe-
guard the public’s health. This pilot program offered cri-
tical lessons and identified key challenges that need to
be addressed for a successful and sustainable national
scale-up. Market forces (price) alone will not increase
access. Specific policy recommendations to assure the
success of this strategy include: expanding the distribu-
tion system by allowing selected ADDOs in remote loca-
tions to resell products to other ADDOs until enough
ADDO-restricted wholesalers are available to meet ACT
as well as other ADDO product source needs; develop-
ing a comprehensive BCC strategy targeting ACTs in
ADDOs; and developing policies that provide the dis-
tricts with the capacity to supervise and inspect ADDOs
to ensure quality of dispensing services and record keep-
ing for accountability and monitoring. In addition,
TFDA needs to continue to address the issue of under-
reporting of sales of prescription-only medicines in the
ADDO drug registers. TFDA should also explore oppor-
tunities offered by new technologies, such as use of cell
phones in data collection and transmission.
ADDO owners’ participation in the pilot, the first of
its kind to deliver subsidized products in Tanzania, was
critical. The program provided incentives in terms of an
adequate profit margin to cover owner operational costs
and small profit. But a majority of ADDO owners and
dispensers participated because they felt this program
enhanced their reputation in the community.
An intervention such as the ADDO program provides
a platform to integrate interventions such as increasing
access to ACT; however, such program requires sub-
stantial human and financial resources, high stakeholder
participation, and time. Other countries planning to use
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ACTs can use such interventions as an initial step
toward more comprehensively addressing the overall
performance of the private sector health system. A drug
seller intervention of limited scope can introduce ACT
distribution with minimal dispenser training; however,
the right path for a broader and more sustainable pro-
gram should be based on innovative uses of the existing
regulatory system, policy change, business incentives,
capacity building, product quality monitoring, and con-
sumer awareness and education.
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